List of Potential Uses for Quantitative SPECT
| Radiopharmaceutical/imaging test | Application |
| Planning/treatment (e.g.,111In,123I, and 177Lu) | Theranostics using quantitative SPECT for targeting and dosimetry planning in monoclonal antibody, peptide, receptor, or other radionuclide therapy (e.g., tositumomab, ibritumomab tiuxetan, and 177Lu-octreotate ) (31,50,51) |
| 99mTc myocardial perfusion imaging | Regional myocardial blood flow in mL⋅100 g−1⋅min−1 (52) or myocardial SUV for detection of left main artery or balanced triple-vessel disease; measurement of coronary flow reserve |
| 99mTc functional lung scanning (ventilation or perfusion) | Preoperative assessment of lobar function before surgical resection (53) |
| 99mTc-macroaggregated albumin | Treatment planning and measuring lung uptake (54) plus estimation radiation dosimetry (55) in selective internal radionuclide therapy for liver cancer before radioembolization |
| 99mTc bone scanning | Quantitative measurement of uptake in metabolic bone disease (56) |
| 123I-iodoamphetamine for regional cerebral blood flow | Baseline/acetazolomide challenge in regional cerebral blood flow (34) |
| 123I-labeled neuroreceptor tracers | Neurotransmitter brain imaging of receptor density and occupancy (57,58) |
| 123I-iodide thyroid uptake | Determination of individualized doses for subsequent radioiodine (131I) therapy and monitoring uptake in follow-up |
| 131I in thyroid cancer | SUV in metastatic thyroid cancer and monitoring response to treatment |
| 201Tl myocardial perfusion imaging | Dynamic analysis of myocardial perfusion to derive kinetic parameters K1 and distribution volume (36) |
| General imaging | Use of quantitative SPECT to monitor serial scans to assess disease progression or response to treatment (e.g., 67Ga in infection) |
| Measuring radionuclide biodistribution and dosimetry | More accurate assessment of 3-dimensional biodistribution and radiation dosimetry from new radiopharmaceuticals (31) |